Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.50 | -$12.99 | -55.30% | 1.3M | $5.4B | $10.11$44.20 |
| PLYX | Polaryx Therapeutics | $5.99 | -$2.92 | -32.77% | 166K | $422M | $2.51$48.91 |
| VHUB | VenHub Global | $3.50 | -$1.33 | -27.54% | 589.4K | $362M | $3.40$40.30 |
| PFSA | Profusa | $3.17 | -$1.20 | -27.50% | 379K | $378M | $2.90$957.00 |
| PGY | Pagaya Technologies | $14.28 | -$4.37 | -23.42% | 826.2K | $1.5B | $8.50$44.99 |
| MNDY | Monday.com | $77.51 | -$20.49 | -20.91% | 474.5K | $5.0B | $73.01$342.64 |
| DBGI | Digital Brands Group | $5.20 | -$1.36 | -20.73% | 646.3K | $54M | $1.06$18.00 |
| FLYE | Fly-E Group | $2.78 | -$0.68 | -19.65% | 304K | $5.6M | $2.50$161.80 |
| MPAA | Motorcar Parts Of America | $10.76 | -$2.39 | -18.15% | 322.5K | $257M | $6.04$18.12 |
| RDIB | Reading International | $11.08 | -$2.38 | -17.68% | 31.2K | $306M | $5.81$17.40 |
| OBAI | Tg-17 | $15.76 | -$3.24 | -17.05% | 28.7K | $61M | $15.06$38.50 |
| IBG | Innovation Beverage Group | $3.97 | -$0.81 | -16.95% | 70.7K | $3.3M | $3.27$49.25 |
| NXTT | Next Technology | $3.10 | -$0.62 | -16.67% | 1.7K | $15M | $3.10$960.00 |
| CLF | Cleveland-Cliffs | $12.39 | -$2.34 | -15.89% | 49.2M | $8.4B | $5.63$16.70 |
| HIMS | Hims & Hers Health | $19.42 | -$3.60 | -15.64% | 3.8M | $5.2B | $16.36$72.98 |
| MAXN | Maxeon Solar Technologies | $3.33 | -$0.56 | -14.40% | 630.8K | $66M | $2.46$6.02 |
| WAT | Waters | $330.98 | -$50.31 | -13.20% | 134.4K | $23B | $275.05$414.15 |
| ASST | Strive Asset Management, Llc | $10.39 | -$1.53 | -12.84% | 105.5K | $397M | $7.73$268.40 |
| ENVB | Enveric Biosciences | $2.12 | -$0.26 | -10.76% | 72.6K | $2.4M | $2.05$54.00 |
Related Articles
Featured Article
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool Staff|Sep 26, 2025
Motley Fool analysts take a look.
